Balaxi Pharmaceuticals Ltd Stock Price Today (NSE: BALAXI)
Fundamental Score
Balaxi Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Balaxi Pharmaceuticals Ltd share price today is ₹20.85, up +0.00% on NSE/BSE as of 17 February 2026. Balaxi Pharmaceuticals Ltd (BALAXI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹200.96 (Cr). The 52-week high for BALAXI share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 13.86x, BALAXI is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.61% and a debt-to-equity ratio of 0.24.
Balaxi Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Balaxi Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Balaxi Pharmaceuticals Share Price: A Growth Strategy Perspective
The pharmaceutical industry, known for its innovation-driven nature, often sees periods of intense competition followed by consolidation, rewarding companies with strong research pipelines and robust distribution networks. This analysis examines the financial standing of Balaxi Pharmaceuticals share price as of today, based on publicly available data, and assesses its potential for sustained growth within this dynamic landscape. At a current price of ₹22.87, with a Price-to-Earnings (PE) ratio of 13.86, Balaxi presents an interesting case study for investors interested in emerging market pharmaceutical players.
A crucial factor for long-term industry dominance is return on capital efficiency. Balaxi Pharmaceuticals demonstrates a Return on Capital Employed (ROCE) of 12.95%. This ROCE indicates the company's effectiveness in generating profits from its invested capital. A consistently strong ROCE can contribute to building a sustainable economic moat, making it more difficult for competitors to erode Balaxi's profitability over time. This efficiency in capital allocation is paramount for outperforming peers and attracting investor confidence.
Comparing Balaxi to its sector peers offers further insights. For instance, while
Mankind Pharma Ltd benefits from a perceived quality in management execution and potentially stronger brand recognition in specific therapeutic areas, Balaxi's current valuation, as reflected in its PE ratio, may indicate a potentially undervalued opportunity or reflect concerns about its relative market position. Furthermore, when compared to Smruthi Organics Ltd and Aurobindo Pharma Ltd, understanding Balaxi’s niche product offerings and geographical focus becomes crucial in judging its long-term viability.This financial analysis, part of a comprehensive 80-parameter fundamental audit personally verified by Sweta Mishra, seeks to provide an objective view of Balaxi Pharmaceuticals. It is essential to note that this analysis is observational and for informational purposes only. It does not constitute financial advice, and prospective investors should conduct their own independent research before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Balaxi Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALAXI across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (16.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 13.86 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (45.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (30.15% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (32.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.24)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (5.48x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (65.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Profit Decline Concern (-95.42%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-27.40%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-57.60 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.52%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Balaxi Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Balaxi Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About BALAXI (Balaxi Pharmaceuticals Ltd)
Balaxi Pharmaceuticals Ltd (BALAXI) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹200.96 (Cr). Balaxi Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 11.61% and a ROCE of 12.95%. The debt-to-equity ratio stands at 0.24, reflecting the company's capital structure. Investors tracking BALAXI share price can monitor key metrics including P/E ratio, promoter holding of 65.99%, and quarterly earnings growth.
Company Details
Corporate Events
BALAXI Share Price: Frequently Asked Questions
What is the current share price of Balaxi Pharmaceuticals Ltd (BALAXI)?
As of 17 Feb 2026, 10:08 am IST, Balaxi Pharmaceuticals Ltd share price is ₹20.85. The BALAXI stock has a market capitalisation of ₹200.96 (Cr) on NSE/BSE.
Is BALAXI share price Overvalued or Undervalued?
BALAXI share price is currently trading at a P/E ratio of 13.86x, compared to the industry average of 31.77x. Based on this relative valuation, the Balaxi Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of BALAXI share price?
The 52-week high of BALAXI share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Balaxi Pharmaceuticals Ltd share price?
Key factors influencing BALAXI share price include quarterly earnings growth (Sales Growth: -27.40%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Balaxi Pharmaceuticals Ltd a good stock for long-term investment?
Balaxi Pharmaceuticals Ltd shows a 5-year Profit Growth of 32.75% and an ROE of 11.61%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.24 before investing in BALAXI shares.
How does Balaxi Pharmaceuticals Ltd compare with its industry peers?
Balaxi Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare BALAXI share price P/E of 13.86x and ROE of 11.61% against the industry averages to determine competitive standing.
What is the P/E ratio of BALAXI and what does it mean?
BALAXI share price has a P/E ratio of 13.86x compared to the industry average of 31.77x. Investors pay ₹14 for every ₹1 of annual earnings.
How is BALAXI performing according to Bull Run's analysis?
BALAXI has a Bull Run fundamental score of 53.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BALAXI belong to?
BALAXI operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Balaxi Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for BALAXI?
BALAXI has an ROE of 11.61%, which shows decent profitability but room for improvement. ROE measures how efficiently Balaxi Pharmaceuticals Ltd generates profits from shareholders capital.
How is BALAXI debt-to-equity ratio and what does it indicate?
BALAXI has a debt-to-equity ratio of 0.24, which indicates conservative financing with low financial risk.
What is BALAXI dividend yield and is it a good dividend stock?
BALAXI offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Balaxi Pharmaceuticals Ltd shares.
How has BALAXI share price grown over the past 5 years?
BALAXI has achieved 5-year growth rates of: Sales Growth 45.01%, Profit Growth 32.75%, and EPS Growth 30.15%.
What is the promoter holding in BALAXI and why does it matter?
Promoters hold 65.99% of BALAXI shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Balaxi Pharmaceuticals Ltd.
What is BALAXI market capitalisation category?
BALAXI has a market capitalisation of ₹201 crores, placing it in the Small-cap category.
How volatile is BALAXI stock?
BALAXI has a beta of N/A. A beta > 1 suggests the Balaxi Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BALAXI operating profit margin trend?
BALAXI has a 5-year average Operating Profit Margin (OPM) of 16.50%, indicating the company's operational efficiency.
How is BALAXI quarterly performance?
Recent quarterly performance shows Balaxi Pharmaceuticals Ltd YoY Sales Growth of -27.40% and YoY Profit Growth of -95.42%.
What is the institutional holding pattern in BALAXI?
BALAXI has FII holding of 3.50% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the Balaxi Pharmaceuticals Ltd stock.